Phaseline

Companies › Clinuvel

Clinuvel: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Immunology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Afamelanotide
Melanocortin receptor 1 agonist
MC1RPhase 3Vitiligo–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06109649AfamelanotidePhase 3VitiligoImmunologyDec 2025

From the company's SEC filings

Cash and short-term investments of $174m on 2026-06-30; operating cash flow positive

Targets

MC1R (1)

Companies with the same targets

Hudson Biotech Tanabe Pharma

Companies built like this

Bioventus ALK-Abelló Kolon TissueGene Doron Therapeutics UnicoCell Biomed

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.